HUP0000125A2 - Folyékony alendronátkészítmények, valamint eljárás azok előállítására - Google Patents
Folyékony alendronátkészítmények, valamint eljárás azok előállításáraInfo
- Publication number
- HUP0000125A2 HUP0000125A2 HU0000125A HUP0000125A HUP0000125A2 HU P0000125 A2 HUP0000125 A2 HU P0000125A2 HU 0000125 A HU0000125 A HU 0000125A HU P0000125 A HUP0000125 A HU P0000125A HU P0000125 A2 HUP0000125 A2 HU P0000125A2
- Authority
- HU
- Hungary
- Prior art keywords
- preparations according
- piles
- approximately
- preparation
- contain
- Prior art date
Links
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940062527 alendronate Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 6
- 239000004480 active ingredient Substances 0.000 abstract 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 229960004343 alendronic acid Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány hatóanyagként alendrőnsavat vagy annak farmakő-lógiaiszempőntból elfőgadható sóját tartalmazó főlyékőnygyógyszerkészítményekre, és ezeknek a gyógyszerkészítményeknek azelőállítására szőlgáló eljárására vőnatkőzik. A találmány szerinti,víztartalmú, főlyékőny gyógyszerkészítmények - hatóanyagkéntalendrőnsavat vagy annak farmakőlógiai szempőntból elfőgadható sóját;- annyi pűffert, hőgy A) a készítmény pH-ja körülbelül 3,5 és körülbelül 7,5 között legyen;és B) 15 ml készítmény képes legyen 50 ml 0,1N sósavőldat pH-ját legalább3-ra növelni; és adőtt esetben - egy vagy több, a tartósítószerek, azízesítőszerek, a színezőanyagők és az édesítőszerek közül kiválasztőttkőmpőnenst tartalmaznak. A találmány szerinti készítményeket úgyállítják elő, hőgy a kőmpőnenseket összekeverik. A találmány szerintikészítményeknek az az előnye, hőgy a csőntfelszívódás gátlása mellettőlyan győmőrpanaszőkat is megszüntetnek, mint a győmőrégés, és abennük lévő pűfferelegyek növelik a hatóanyagők biőlógiaihasznősíthatóságát. ŕ
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2676596P | 1996-10-04 | 1996-10-04 | |
| GBGB9700541.7A GB9700541D0 (en) | 1997-01-13 | 1997-01-13 | Liquid alendronate formulation |
| US3600297P | 1997-01-22 | 1997-01-22 | |
| PCT/US1997/015740 WO1998014196A1 (en) | 1996-10-04 | 1997-10-02 | Liquid alendronate formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0000125A2 true HUP0000125A2 (hu) | 2000-06-28 |
| HUP0000125A3 HUP0000125A3 (en) | 2001-04-28 |
Family
ID=27268667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0000125A HUP0000125A3 (en) | 1996-10-04 | 1997-10-02 | Liquid alendronate formulations and producing them |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1007054A4 (hu) |
| JP (1) | JP2001501222A (hu) |
| CN (1) | CN1238691A (hu) |
| AU (1) | AU723357B2 (hu) |
| BG (1) | BG103306A (hu) |
| BR (1) | BR9712197A (hu) |
| CA (1) | CA2267370A1 (hu) |
| CZ (1) | CZ116999A3 (hu) |
| EA (1) | EA001213B1 (hu) |
| EE (1) | EE03669B1 (hu) |
| HU (1) | HUP0000125A3 (hu) |
| IL (1) | IL129127A0 (hu) |
| IS (1) | IS5012A (hu) |
| NO (1) | NO991569L (hu) |
| NZ (1) | NZ334836A (hu) |
| PL (1) | PL332496A1 (hu) |
| SK (1) | SK42999A3 (hu) |
| TR (1) | TR199900730T2 (hu) |
| WO (1) | WO1998014196A1 (hu) |
| YU (1) | YU17499A (hu) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2243457T3 (es) * | 2001-01-23 | 2005-12-01 | Gador S.A. | Composicion que comprende bifosfonatos para la prevencion y/o tratamiento de trastornos metabolicos de huesos, procedimiento de preparacion de dicha composicion y usos de la misma. |
| US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
| US20080286359A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US20080287400A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| US7473684B2 (en) | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
| EP1937362B1 (en) * | 2005-09-16 | 2013-03-27 | Selamine Ltd. | Bisphosphonate formulation |
| JP2010043119A (ja) * | 2009-10-16 | 2010-02-25 | Gador Sa | 骨の代謝病の予防および／または治療のための組成物、その組成物の調製方法およびその使用 |
| US8568747B1 (en) | 2012-10-05 | 2013-10-29 | Silvergate Pharmaceuticals, Inc. | Enalapril compositions |
| US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
| US9669008B1 (en) | 2016-03-18 | 2017-06-06 | Silvergate Pharmaceuticals, Inc. | Enalapril formulations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4206209A (en) * | 1978-11-02 | 1980-06-03 | Kracauer Paul | Sublingual aspirin tablet |
| IT1201087B (it) * | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| US5019651A (en) * | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| FR2703590B1 (fr) * | 1993-04-05 | 1995-06-30 | Sanofi Elf | Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse . |
| US5510517A (en) * | 1993-08-25 | 1996-04-23 | Merck & Co., Inc. | Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids |
| US5462932A (en) * | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
| US5780455A (en) * | 1994-08-24 | 1998-07-14 | Merck & Co., Inc. | Intravenous alendronate formulations |
| US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
-
1997
- 1997-10-02 PL PL97332496A patent/PL332496A1/xx unknown
- 1997-10-02 BR BR9712197-5A patent/BR9712197A/pt unknown
- 1997-10-02 WO PCT/US1997/015740 patent/WO1998014196A1/en not_active Application Discontinuation
- 1997-10-02 NZ NZ334836A patent/NZ334836A/xx unknown
- 1997-10-02 CA CA002267370A patent/CA2267370A1/en not_active Abandoned
- 1997-10-02 EP EP97945195A patent/EP1007054A4/en not_active Withdrawn
- 1997-10-02 TR TR1999/00730T patent/TR199900730T2/xx unknown
- 1997-10-02 SK SK429-99A patent/SK42999A3/sk unknown
- 1997-10-02 CZ CZ991169A patent/CZ116999A3/cs unknown
- 1997-10-02 EA EA199900352A patent/EA001213B1/ru not_active IP Right Cessation
- 1997-10-02 IL IL12912797A patent/IL129127A0/xx unknown
- 1997-10-02 HU HU0000125A patent/HUP0000125A3/hu unknown
- 1997-10-02 AU AU46448/97A patent/AU723357B2/en not_active Ceased
- 1997-10-02 EE EEP199900113A patent/EE03669B1/xx not_active IP Right Cessation
- 1997-10-02 JP JP10516541A patent/JP2001501222A/ja active Pending
- 1997-10-02 CN CN97180165A patent/CN1238691A/zh active Pending
-
1999
- 1999-03-26 IS IS5012A patent/IS5012A/is unknown
- 1999-03-30 NO NO991569A patent/NO991569L/no not_active Application Discontinuation
- 1999-03-31 YU YU17499A patent/YU17499A/sr unknown
- 1999-04-02 BG BG103306A patent/BG103306A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9712197A (pt) | 1999-08-31 |
| EE03669B1 (et) | 2002-04-15 |
| EP1007054A4 (en) | 2000-07-19 |
| AU723357B2 (en) | 2000-08-24 |
| NO991569L (no) | 1999-06-04 |
| EE9900113A (et) | 1999-10-15 |
| NZ334836A (en) | 2000-11-24 |
| EA199900352A1 (ru) | 1999-08-26 |
| JP2001501222A (ja) | 2001-01-30 |
| CA2267370A1 (en) | 1998-04-09 |
| TR199900730T2 (xx) | 1999-07-21 |
| EA001213B1 (ru) | 2000-12-25 |
| HUP0000125A3 (en) | 2001-04-28 |
| BG103306A (en) | 2000-01-31 |
| CN1238691A (zh) | 1999-12-15 |
| IL129127A0 (en) | 2000-02-17 |
| IS5012A (is) | 1999-03-26 |
| WO1998014196A1 (en) | 1998-04-09 |
| SK42999A3 (en) | 2000-01-18 |
| CZ116999A3 (cs) | 1999-09-15 |
| EP1007054A1 (en) | 2000-06-14 |
| AU4644897A (en) | 1998-04-24 |
| NO991569D0 (no) | 1999-03-30 |
| PL332496A1 (en) | 1999-09-13 |
| YU17499A (en) | 1999-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2087146A1 (en) | Flavour-masked pharmaceutical compositions | |
| DE69940769D1 (de) | Orale flüssige zusammensetzungen | |
| TR200003158T2 (tr) | Jelleşebilen farmasötik bileşimler | |
| TR200102314T2 (tr) | Damar gelişimi inhibitörleri olarak kuinazolin türevleri. | |
| ATE209898T1 (de) | Feste arzneizubereitung | |
| HUP0102039A2 (hu) | Albuminnal stabilizált paclitaxel alkalmazása tömör tumorok kezelésére szolgáló gyógyszerkészítmények előállítására, és a kapott gyógyszerkészítmények | |
| CS653586A3 (en) | Pharmaceutical containing 7-isopropoxyisoflavone | |
| HUP0302114A2 (hu) | Eritropoietin-fehérjét tartalmazó folyékony gyógyászati készítmény, eljárás előállítására és alkalmazása | |
| BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
| ATE353009T1 (de) | Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen | |
| NZ501950A (en) | Medicinal compositions for application to mucosa | |
| DE60024491D1 (de) | Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne | |
| CA2282082A1 (fr) | Microgranules contenant du cisplatine | |
| BG105173A (en) | Novel salt form of pantoprazole | |
| HUP0000125A2 (hu) | Folyékony alendronátkészítmények, valamint eljárás azok előállítására | |
| ATE66605T1 (de) | Waessrige arzneiformulierungen des piroxicammonohydrats. | |
| ES2274318T3 (es) | Compuestos cuaternarios que comprenden propolis como sustancia activa. | |
| WO1999047172A3 (en) | Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes | |
| BR9912533A (pt) | Composição farmacêutica tendo sabor melhorado | |
| IT1204777B (it) | Composizione per la preparazione estemporanea di formulazioni per applicazioni topiche per uso farmaceutico e cosmetico | |
| WO2003061557A3 (en) | Levothyroxine pharmaceutical compositions, methods of making and methods of administration | |
| GEP20043377B (en) | Pharmaceutical Complex | |
| ATE347886T1 (de) | Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen | |
| CA2429793A1 (en) | Interferon therapeutic effect enhancer | |
| CA2259270A1 (en) | Pharmaceutical preparation containing nimesulide for oral administration |